Literature DB >> 28282562

Synthesis, characterization and biological evaluation of ruthenium flavanol complexes against breast cancer.

Ashok Kumar Singh1, Gunjan Saxena2, M Arshad3.   

Abstract

Four Ru(II) DMSO complexes (M1R-M4R) having substituted flavones viz. 3-Hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one (HL1), 3-Hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (HL2), 3-Hydroxy-2-(4-dimethylaminophenyl)-4H-chromen-4-one (HL3) and 3-Hydroxy-2-(4-chlorophenyl)-4H-chromen-4-one (HL4) were synthesized and characterized by elemental analysis, IR, UV-Vis, 1H NMR spectroscopies and ESI-MS. The molecular structures of the complexes were investigated by integrated spectroscopic and computational techniques (DFT). Both ligands as well as their complexes were screened for anticancer activities against breast cancer cell lines MCF-7. Cytotoxicity was assayed by MTT [3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay. All ligands and their complexes exhibited significant cytotoxic potential of 5-40μM concentration at incubation period of 24h. The cell cytotoxicity increased significantly in a concentration-dependent manner. In this series of compounds, HL2 (IC50 17.2μM) and its complex M2R (IC50 16μM) induced the highest cytotoxicity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; DFT; DMSO; Flavones; Ru(II)

Mesh:

Substances:

Year:  2017        PMID: 28282562     DOI: 10.1016/j.saa.2017.02.056

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  3 in total

1.  Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.

Authors:  Cinara O D'Sousa Costa; João H Araujo Neto; Ingrid R S Baliza; Rosane B Dias; Ludmila de F Valverde; Manuela T A Vidal; Caroline B S Sales; Clarissa A G Rocha; Diogo R M Moreira; Milena B P Soares; Alzir A Batista; Daniel P Bezerra
Journal:  Oncotarget       Date:  2017-11-01

Review 2.  Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.

Authors:  Golara Golbaghi; Annie Castonguay
Journal:  Molecules       Date:  2020-01-09       Impact factor: 4.411

3.  A Novel Synthetic Compound (E)-5-((4-oxo-4H-chromen-3-yl)methyleneamino)-1-phenyl-1H-pyrazole-4-carbonitrile Inhibits TNFα-Induced MMP9 Expression via EGR-1 Downregulation in MDA-MB-231 Human Breast Cancer Cells.

Authors:  Munki Jeong; Euitaek Jung; Young Han Lee; Jeong Kon Seo; Seunghyun Ahn; Dongsoo Koh; Yoongho Lim; Soon Young Shin
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.